{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:11:26Z","timestamp":1791724286254,"version":"4.3.4"},"reference-count":96,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ad.2017.07.018","type":"journal-article","created":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T03:36:25Z","timestamp":1516160185000},"page":"207-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["S\u00edndrome de Gorlin"],"prefix":"10.1016","volume":"109","author":[{"given":"I.","family":"Palacios-\u00c1lvarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Gonz\u00e1lez-Sarmiento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Fern\u00e1ndez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2017.07.018_bib0485","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00005792-198703000-00002","article-title":"Nevoid basal-cell carcinoma syndrome","volume":"66","author":"Gorlin","year":"1987","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ad.2017.07.018_bib0490","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0092-8674(00)81268-4","article-title":"Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome","volume":"85","author":"Hahn","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.ad.2017.07.018_bib0495","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1126\/science.272.5268.1668","article-title":"Human homolog of patched, a candidate gene for the basal cell nevus syndrome","volume":"272","author":"Johnson","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ad.2017.07.018_bib0500","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nrc2503","article-title":"Basal cell carcinomas: attack of the hedgehog","volume":"8","author":"Epstein","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ad.2017.07.018_bib0505","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1038\/skinbio.2014.4","article-title":"Basal cell carcinoma. Hedgehog signaling, and targeted therapeutics: the long and winding road","volume":"134","author":"Wong","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2017.07.018_bib0510","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service","volume":"152A","author":"Evans","year":"2010","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.ad.2017.07.018_bib0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ejhg.2012.299","article-title":"Clinical utility gene card for: Gorlin syndrome--update 2013","volume":"21","author":"Lo Muzio","year":"2013","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.ad.2017.07.018_bib0520","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0140-6736(92)90868-4","article-title":"Location of gene for Gorlin syndrome","volume":"339","author":"Farndon","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2017.07.018_bib0525","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/jmedgenet-2011-100562","article-title":"Life expectancy in hereditary cancer predisposing diseases: an observational study","volume":"49","author":"Wilding","year":"2012","journal-title":"J Med Genet"},{"key":"10.1016\/j.ad.2017.07.018_bib0530","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1750-1172-3-32","article-title":"Nevoid basal cell carcinoma syndrome (Gorlin syndrome)","volume":"3","author":"Lo Muzio","year":"2008","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ad.2017.07.018_bib0535","series-title":"GeneReviews [Internet]","article-title":"Nevoid basal cell carcinoma syndrome","author":"Evans","year":"1993"},{"key":"10.1016\/j.ad.2017.07.018_bib0540","doi-asserted-by":"crossref","first-page":"795:801","DOI":"10.1038\/287795a0","article-title":"Mutations affecting segment number and polarity in Drosophila","volume":"287","author":"N\u00fcsslein-Volhard","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.ad.2017.07.018_bib0545","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.2147\/OTT.S34678","article-title":"Targeting hedgehog signaling in cancer: research and clinical developments","volume":"6","author":"Xie","year":"2013","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ad.2017.07.018_bib0550","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1158\/0008-5472.CAN-14-1666","article-title":"Sonic hedgehog signaling in basal cell nevus syndrome","volume":"74","author":"Athar","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.ad.2017.07.018_bib0555","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/jid.2013.276","article-title":"Mutational landscape of basal cell carcinomas by whole-exome sequencing","volume":"134","author":"Jayaraman","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2017.07.018_bib0560","doi-asserted-by":"crossref","first-page":"re6","DOI":"10.1126\/scisignal.2002906","article-title":"The hedgehog signal transduction network","volume":"5","author":"Robbins","year":"2012","journal-title":"Sci Signal"},{"key":"10.1016\/j.ad.2017.07.018_bib0565","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccr.2011.12.028","article-title":"The Crosstalk of mTOR\/S6K1 and Hedgehog pathways","volume":"21","author":"Wang","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ad.2017.07.018_bib0570","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/01.gim.0000182879.57182.b4","article-title":"Clinical testing for the nevoid basal cell carcinoma syndrome in a DNA diagnostic laboratory","volume":"7","author":"Klein","year":"2005","journal-title":"Genet Med"},{"key":"10.1016\/j.ad.2017.07.018_bib0575","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/humu.9365","article-title":"DHPLC analysis of patients with nevoid basal cell carcinoma syndrome reveals novel PTCH missense mutations in the sterol-sensing domain","volume":"26","author":"Marsh","year":"2005","journal-title":"Hum Mutat"},{"key":"10.1016\/j.ad.2017.07.018_bib0580","doi-asserted-by":"crossref","first-page":"217378","DOI":"10.1155\/2011\/217378","article-title":"Basal cell carcinomas in gorlin syndrome: a review of 202 patients","volume":"2011","author":"Jones","year":"2011","journal-title":"J Skin Cancer"},{"key":"10.1016\/j.ad.2017.07.018_bib0585","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1111\/dsu.12241","article-title":"PTCH\u201d-ing It Together: A Basal Cell Nevus Syndrome Review","volume":"39","author":"Lam","year":"2013","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ad.2017.07.018_bib0590","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1200\/JCO.2014.58.2569","article-title":"Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations","volume":"32","author":"Smith","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2017.07.018_bib0595","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/ped.12461","article-title":"Gorlin syndrome (nevoid basal cell carcinoma syndrome): update and literature review","volume":"56","author":"Fujii","year":"2014","journal-title":"Pediatr Int"},{"key":"10.1016\/j.ad.2017.07.018_bib0600","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/jmg.30.6.460","article-title":"Complications of the naevoid basal cell carcinoma syndrome: results of a population based study","volume":"30","author":"Evans","year":"1993","journal-title":"J Med Genet"},{"key":"10.1016\/j.ad.2017.07.018_bib0605","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajmg.1320500312","article-title":"Nevoid basal cell carcinoma syndrome: review of 118 affected individuals","volume":"50","author":"Shanley","year":"1994","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.ad.2017.07.018_bib0610","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/ajmg.a.34128","article-title":"Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS)","volume":"155A","author":"Bree","year":"2011","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.ad.2017.07.018_bib0615","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/(SICI)1096-8628(19970331)69:3<299::AID-AJMG16>3.0.CO;2-M","article-title":"Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome","volume":"69","author":"Kimonis","year":"1997","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.ad.2017.07.018_bib0620","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/01.GIM.0000145045.17711.1C","article-title":"Radiological features in 82 patients with nevoid basal cell carcinoma (NBCC or Gorlin) syndrome","volume":"6","author":"Kimonis","year":"2004","journal-title":"Genet Med"},{"key":"10.1016\/j.ad.2017.07.018_bib0625","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1002\/ajmg.a.34127","article-title":"Features of basal cell carcinomas in basal cell nevus syndrome","volume":"155A","author":"Tom","year":"2011","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.ad.2017.07.018_bib0630","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1600-0560.2012.01984.x","article-title":"Palmar pits associated with the nevoid basal cell carcinoma syndrome","volume":"39","author":"North","year":"2012","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.ad.2017.07.018_bib0635","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/gim.2012.96","article-title":"Clinical and radiological features in young individuals with nevoid basal cell carcinoma syndrome","volume":"15","author":"Kimonis","year":"2013","journal-title":"Genet. Med"},{"key":"10.1016\/j.ad.2017.07.018_bib0640","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1259\/0007-1285-68-808-361","article-title":"The diagnostic implication of falcine calcification on plain skull radiographs of patients with basal cell naevus syndrome and the incidence of falcine calcification in their relatives and two control groups","volume":"68","author":"Ratcliffe","year":"1995","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ad.2017.07.018_bib0645","doi-asserted-by":"crossref","first-page":"RA145","DOI":"10.12659\/MSM.883341","article-title":"Gorlin-Goltz syndrome \u2013 a medical condition requiring a multidisciplinary approach","volume":"18","author":"Kiwilsza","year":"2012","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.ad.2017.07.018_bib0650","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/ajmg.a.34421","article-title":"Nationwide survey of nevoid basal cell carcinoma syndrome in japan revealing the low incidence of basal cell carcinoma","volume":"158A","author":"Endo","year":"2012","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.ad.2017.07.018_bib0655","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1259\/0007-1285-68-810-596","article-title":"The prevalence of cervical and thoracic congenital skeletal abnormalities in basal cell naevus syndrome; a review of cervical and chest radiographs in 80 patients with BCNS","volume":"68","author":"Ratcliffe","year":"1995","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ad.2017.07.018_bib0660","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1034\/j.1399-0004.1999.550106.x","article-title":"Nevoid basal cell carcinoma syndrome. Clinical findings in 37 Italian affected individuals","volume":"55","author":"Lo Muzio","year":"1999","journal-title":"Clin Genet"},{"key":"10.1016\/j.ad.2017.07.018_bib0665","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/bjo.80.4.378","article-title":"Microphthalmos in association with Gorlin's syndrome","volume":"80","author":"Manners","year":"1996","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ad.2017.07.018_bib0670","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/cncr.11537","article-title":"Nevoid basal cell carcinoma syndrome: relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature","volume":"98","author":"Amlashi","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ad.2017.07.018_bib0675","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nrc3410","article-title":"Medulloblastomics: The End of the Beginning","volume":"12","author":"Northcott","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ad.2017.07.018_bib0680","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00428-011-1108-8","article-title":"Mediastinal fetal rhabdomyoma in nevoid basal cell carcinoma syndrome: a case report and review of the literature","volume":"459","author":"Yang","year":"2011","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ad.2017.07.018_bib0685","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2340\/00015555-1892","article-title":"Naevoid basal cell carcinoma syndrome in a 22-month-old child presenting with multiple basal cell carcinomas and a fetal rhabdomyoma","volume":"95","author":"Diociaiuti","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2017.07.018_bib0690","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/bjd.14206","article-title":"Basal cell naevus syndrome: An update on genetics and treatment","volume":"174","author":"John","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2017.07.018_bib0695","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/09546634.2012.746634","article-title":"Retinoids in the chemoprevention of non-melanoma skin cancers: why, when and how","volume":"24","author":"Bettoli","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2017.07.018_bib0700","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1158\/1940-6207.CAPR-13-0305","article-title":"Tazarotene: Randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndrome","volume":"7","author":"Tang","year":"2014","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.ad.2017.07.018_bib0705","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1440-0960.2012.00922.x","article-title":"A possible chemopreventive role for photodynamic therapy in Gorlin syndrome: A report of basal cell carcinoma reduction and review of literature","volume":"54","author":"Wolfe","year":"2013","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.ad.2017.07.018_bib0710","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/cancers8100098","article-title":"Photodynamic Therapy and Non-Melanoma Skin Cancer","volume":"8","author":"Griffin","year":"2016","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ad.2017.07.018_bib0715","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1056\/NEJMra044151","article-title":"Basal-cell carcinoma","volume":"353","author":"Rubin","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2017.07.018_bib0720","doi-asserted-by":"crossref","first-page":"574","DOI":"10.6004\/jnccn.2016.0065","article-title":"Basal Cell Skin Cancer, Version 1.2016. NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Bichakjian","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ad.2017.07.018_bib0725","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1468-3083.2008.03040.x","article-title":"Treatment of basal cell carcinomas in patients with nevoid basal cell carcinoma syndrome","volume":"23","author":"van der Geer","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2017.07.018_bib0730","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2133.2008.08666.x","article-title":"British Association of Dermatologists. Guidelines for the management of basal cell carcinoma","volume":"159","author":"Telfer","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2017.07.018_bib0735","first-page":"467","article-title":"Guidelines: The management of basal cell carcinoma","volume":"16","author":"Sterry","year":"2006","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ad.2017.07.018_bib0740","first-page":"287","article-title":"Ultrapulse CO2 used for the successful treatment of basal cell carcinomas found in patients with basal cell nevus syndrome","volume":"28","author":"Nouri","year":"2002","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ad.2017.07.018_bib0745","first-page":"1236","article-title":"Full-face carbon dioxide laser resurfacing in the management of a patient with the nevoid basal cell carcinoma syndrome","volume":"29","author":"Doctoroff","year":"2003","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ad.2017.07.018_bib0750","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1346-8138.1998.tb02337.x","article-title":"Microscopically controlled surgical excision combined with ultrapulse CO2 vaporization in the management of a patient with the nevoid basal cell carcinoma syndrome","volume":"25","author":"Krunic","year":"1998","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2017.07.018_bib0755","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jdv.12031","article-title":"European guidelines for topical photodynamic therapy part 1: Treatment delivery and current indications - Actinic keratoses. Bowen's disease, basal cell carcinoma","volume":"27","author":"Morton","year":"2013","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"10.1016\/j.ad.2017.07.018_bib0760","first-page":"547","article-title":"Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial","volume":"18","author":"Basset-Seguin","year":"2008","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ad.2017.07.018_bib0765","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/j.1468-3083.2008.02803.x","article-title":"A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20mm), with a 12-month follow-up","volume":"22","author":"Szeimies","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2017.07.018_bib0770","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/jdv.12150","article-title":"Consensus recommendations for the treatment of basal cell carcinomas in Gorlin syndrome with topical methylaminolaevulinate-photodynamic therapy","volume":"28","author":"Basset-Seguin","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2017.07.018_bib0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2013.12.037","article-title":"Topical pharmacotherapy for skin cancer: part I Pharmacology","volume":"70","author":"Micali","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2017.07.018_bib0780","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11096-006-9030-x","article-title":"Total body topical 5-fluorouracil for extensive non-melanoma skin cancer","volume":"28","author":"Van Ruth","year":"2006","journal-title":"Pharm World Sci"},{"key":"10.1016\/j.ad.2017.07.018_bib0785","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000249725","article-title":"Basal cell nevus syndrome. Unresponsiveness of early cutaneous lesions to topical 5-fluorouracil or dinitrochlorobenzen","volume":"168","author":"Hazen","year":"1984","journal-title":"Dermatologica"},{"key":"10.1016\/j.ad.2017.07.018_bib0790","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1346-8138.1993.tb01330.x","article-title":"Cryosurgery and topical fluorouracil: a treatment method for widespread basal cell epithelioma in basal cell nevus syndrome","volume":"20","author":"Tsuji","year":"1993","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2017.07.018_bib0795","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/0190-9622(92)70262-E","article-title":"Long-term management of basal cell nevus syndrome with topical tretinoin and 5-fluorouracil","volume":"27","author":"Strange","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2017.07.018_bib0800","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1200\/JCO.2010.33.3393","article-title":"Novel approach to Gorlin syndrome: a patient treated with oral capecitabine","volume":"29","author":"Beach","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2017.07.018_bib0805","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jaad.2003.11.066","article-title":"Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies","volume":"50","author":"Geisse","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2017.07.018_bib0810","first-page":"374","article-title":"Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe","volume":"15","author":"Gollnick","year":"2005","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ad.2017.07.018_bib0815","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1365-2230.28.s1.7.x","article-title":"The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin's syndrome","volume":"28","author":"Micali","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2017.07.018_bib0820","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1468-3083.2006.01552.x","article-title":"Hundreds of basal cell carcinomas in a Gorlin\u2013Goltz syndrome patient cured with imiquimod 5% cream","volume":"20","author":"Ferreres","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2017.07.018_bib0825","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/09546630310017825","article-title":"Topical application of imiquimod for the treatment of high-risk facial basal cell carcinoma in Gorlin syndrome","volume":"15","author":"Vereecken","year":"2004","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.ad.2017.07.018_bib0830","first-page":"569","article-title":"Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod","volume":"12","author":"Stockfleth","year":"2002","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ad.2017.07.018_bib0835","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000447394","article-title":"Ingenol mebutate treatment in a patient with Gorlin syndrome","volume":"232","author":"Stieger","year":"2016","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2017.07.018_bib0840","unstructured":"Ficha t\u00e9cnica de vismodegib. [consultado 25 May 2017].Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/002602\/WC500146817.pdf."},{"key":"10.1016\/j.ad.2017.07.018_bib0845","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","article-title":"Inhibition of the hedgehog pathway in advanced basal-cell carcinoma","volume":"361","author":"Von Hoff","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2017.07.018_bib0850","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2017.07.018_bib0855","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaad.2015.03.021","article-title":"Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC","volume":"72","author":"Sekulic","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2017.07.018_bib0860","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2013.09.012","article-title":"Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib","volume":"70","author":"Chang","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2017.07.018_bib0865","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1470-2045(15)70198-1","article-title":"Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial","volume":"16","author":"Basset-Seguin","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ad.2017.07.018_bib0870","first-page":"9023","article-title":"The regiSONIC disease registry: Preliminary effectiveness and safety in the first 66 newly diagnosed locally advanced basal cell carcinoma (BCC) patients treated with vismodegib","volume":"33","author":"Lacouture","year":"2015","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.ad.2017.07.018_bib0875","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13023-016-0506-z","article-title":"Day B-M, et al. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials","volume":"11","author":"Chang","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ad.2017.07.018_bib0880","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jamadermatol.2013.7444","article-title":"The use of vismodegib to shrink keratocystic odontogenic tumors in patients with basal cell nevus syndrome","volume":"150","author":"Ally","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2017.07.018_bib0885","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S1470-2045(17)30072-4","article-title":"Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial","volume":"18","author":"Dr\u00e9no","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ad.2017.07.018_bib0890","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1113538","article-title":"Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome","volume":"366","author":"Tang","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2017.07.018_bib0895","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/S1470-2045(16)30566-6","article-title":"Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Tang","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ad.2017.07.018_bib0900","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/jamadermatol.2015.3210","article-title":"Intermittent vismodegib therapy in basal cell nevus syndrome","volume":"152","author":"Yang","year":"2016","journal-title":"JAMA Dermatology"},{"key":"10.1016\/j.ad.2017.07.018_bib0905","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1126\/science.1179386","article-title":"Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma","volume":"326","author":"Yauch","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ad.2017.07.018_bib0910","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1158\/0008-5472.CAN-10-2876","article-title":"Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance","volume":"71","author":"Dijkgraaf","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.ad.2017.07.018_bib0915","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jamadermatol.2015.4330","article-title":"Increased risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal cell carcinoma","volume":"152","author":"Mohan","year":"2016","journal-title":"JAMA Dermatology"},{"key":"10.1016\/j.ad.2017.07.018_bib0920","unstructured":"Ficha t\u00e9cnica de Sonidegib. [consultado 25 May 2017]. Disponible en: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2015\/20150814132561\/anx_132561_es.pdf."},{"key":"10.1016\/j.ad.2017.07.018_bib0925","first-page":"129","article-title":"Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors","volume":"9","author":"Fecher","year":"2015","journal-title":"Biologics"},{"key":"10.1016\/j.ad.2017.07.018_bib0930","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/1078-0432.CCR-15-1588","article-title":"An investigator-initiated open-label trial of sonidegib in advanced basal cell carcinoma patients resistant to vismodegib","volume":"22","author":"Danial","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ad.2017.07.018_bib0935","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/jid.2011.48","article-title":"Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor","volume":"131","author":"Skvara","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2017.07.018_bib0940","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1158\/1078-0432.CCR-12-3654","article-title":"Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors","volume":"19","author":"Jimeno","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ad.2017.07.018_bib0945","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ccr.2010.02.027","article-title":"Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth","volume":"17","author":"Kim","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ad.2017.07.018_bib0950","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1200\/JCO.2013.49.9525","article-title":"Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma","volume":"32","author":"Kim","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2017.07.018_bib0955","doi-asserted-by":"crossref","first-page":"13432","DOI":"10.1073\/pnas.1006822107","article-title":"Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector","volume":"107","author":"Kim","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.ad.2017.07.018_bib0960","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ccr.2012.11.017","article-title":"Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists","volume":"23","author":"Kim","year":"2013","journal-title":"Cancer Cell"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731017305379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731017305379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:06:47Z","timestamp":1757552807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731017305379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":96,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0001731017305379"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2017.07.018","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"S\u00edndrome de Gorlin","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2017.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 AEDV. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}